Saturday 17 October 2026
Export XBIO’s income statement to Excel — free account
Xenetic Biosciences, Inc.
XBIO Healthcare Biotechnology
Xenetic Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 19.0% from fiscal 2024. In the quarter to June 2026, revenue grew 12.0%, EPS grew 8.89% and free cash flow fell 128.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.98
0.03
−1.49%
Follow XBIO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 4 | 5 | 3 |
+8 more TTM periods Free account |
| (47.05%) | (37.02%) | (40.01%) | (57.44%) | ||
| (40.17%) | (32.61%) | (35.12%) | (48.13%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(42.98%) | (33.66%) | (37.85%) | (79.78%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.01) | (0.79) | (1.34) | (1.76) | |
Free Cash Flow |
(2.31) | (1.82) | (2.29) | (2.72) | |
| Other line items | |||||
Cash ROIC |
(18.44%) | (12.74%) | (14.97%) | (33.65%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
84.13% | 89.27% | 102.99% | 116.63% | |
Selling, General and Administrative Expense of Revenue |
96.88% | 85.78% | 92.24% | 99.17% | |
Share Based Compensation of Revenue |
2.86% | 1.78% | 2.18% | 2.65% | |
Operating CF/Net income |
0.93 | 0.82 | 0.85 | 0.86 | |
Revenue per Share |
1.42 | 1.39 | 1.75 | 1.85 | |
Operating CF per Share |
(1.01) | (0.79) | (1.34) | (1.76) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates